North America to Dominate Neoantigen Cancer Vaccine Market through 2026
Rising prevalence of cancer and increasing adoption of
personalized medicine to drive the growth of global neoantigen cancer vaccine
market.
According to TechSci Research report, “Global Neoantigen
Cancer Vaccine Market By Product (Personalized neoantigen vaccine, Off-the
shelf neoantigen vaccine), By Neoantigen Type (Synthetic long peptide (SLP), Nucleic
Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous,
Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology
(RNA sequencing, Whole genome sequencing, HLA typing), By Delivery Mechanism (Liposomes,
Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma,
Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2026”, global neoantigen cancer vaccine market is expected to reach
USD1754.44 million in 2026, growing with double-digit CAGR of 54.18% during the
forecast period. Neoantigen cancer vaccines are the type of vaccines that help to
boost the immune system with the help of single or several antigens.
Surging prevalence of cancer is one of the major factors accounting for
the growth of global neoantigen cancer vaccine market. Moreover, rapid adoption
of personalized medicines for the patient’s treatment on individual level is
further expected to aid in the growth of global neoantigen cancer vaccine market
through the forecast period. The product type is segmented into personalized
neoantigen vaccine and off-the shelf neoantigen vaccine. The personalized
neoantigen vaccine is expected to dominate the market in the forecast period due
to high number of clinical trials and extensive R&D for the development of personalized
neoantigen cancer vaccines.
In addition to this, continuous advancements in several drug delivery technologies
is anticipated to positively influence the growth of the global neoantigen
cancer vaccine market in the years to come. Also, increased funding for
executing research and development activities is making headway for the growth
of global neoantigen cancer vaccine market across the globe. Along with this, expected
launch of first neoantigen vaccine Tedopi in the market, is estimated to boost
the market growth through 2026. However, high cost of personalized cancer
vaccines as well as obstacles in clinical development are the major factors
that might restrain the growth of the global neoantigen cancer vaccine market
through 2026.
Browse 3 market data Tables and 223
Figures spread through 284 Pages and an in-depth TOC on "Global
Neoantigen Cancer Vaccine Market"
https://www.techsciresearch.com/report/neoantigen-cancer-vaccine-market/4566.html
Global neoantigen cancer vaccine market can be segmented based on product,
neoantigen type, route of administration, cell, technology, delivery mechanism,
application, company, and region. Considering the delivery
mechanism, the market is fragmented into liposomes, virosomes electroporation,
gene gun, and others. The liposomes segment is anticipated to grow at the high
rate during the forecast period. In terms of technology, the market is fragmented
into RNA sequencing, whole genome sequencing, and HLA typing. Out of which, RNA
sequencing technology segment is forecast to register high growth in the next 5
years on account of studying what genes are mis regulated.
OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F.
Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea
Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene
Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath
Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences
Inc., Advaxis, Inc., Nouscom AG among others are the leading players operating
in global neoantigen cancer vaccine market. The leading
players are adopting several growth strategies to enhance the market scenario
of neoantigen cancer vaccine. Some of the competitive strategies include partnerships,
collaborations, business expansions, as well as mergers and acquisitions,
partnership opportunities in order to diverse their product portfolio and to
strengthen their market position.
Download sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=4566
Customers can also request for 10% free customization on this report.
“North America is
forecast to dominate the global neoantigen cancer vaccine market with a highest
market share among all the regions during the next five years on the account of
the existence of many key market players in this region. Asia-Pacific is anticipated
to register high growth during the forecast period which can be accredited to
rising population that has cancer and significant number of clinical trials
going on in China. Furthermore, mounting investment in research activities and
improvement in healthcare technologies is expected to aid the growth of neoantigen
cancer vaccine market in the region until 2026.”, said Mr. Karan Chechi,
Research Director with TechSci Research, a research based global management
consulting firm.
“Global Neoantigen Cancer
Vaccine Market By Product (Personalized neoantigen vaccine, Off-the shelf
neoantigen vaccine), By Neoantigen Type (Synthetic long peptide (SLP), Nucleic
Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous,
Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology
(RNA sequencing, Whole genome sequencing, HLA typing), By Delivery Mechanism (Liposomes,
Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma,
Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities,
2026”
has evaluated the future growth potential of global neoantigen cancer vaccine market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global neoantigen cancer vaccine market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/